文献速递慢性肾脏病

CONCORD试验:CKD抑郁新型疗法的设计与基线特征

Design and Baseline Characteristics of CONCORD, a Trial of Novel Therapies for Depression in CKD.
PubMed 文献 · Kidney Int Rep · 2026-08-20

CONCORD是一项多中心随机安慰剂对照试验,评估安非他酮、行为激活远程治疗(BAT)及联合方案对CKD G3b-5合并重度抑郁障碍(MDD)的疗效。共随机202例患者,平均年龄56岁,平均eGFR 24.6 ml/min/1.73 m²。主要结局为16周抑郁严重度改善。

要点

  • CONCORD针对CKD G3b-5合并MDD患者,比较安非他酮、BAT及联合治疗与对照的疗效。
  • 研究纳入202例患者,平均eGFR 24.6 ml/min/1.73 m²,覆盖CKD G3b至G5D。
  • 主要结局为16周抑郁严重度较基线改善,同时评估安全性和耐受性。

核心结论

  • CONCORD将为安非他酮、BAT及联合治疗改善CKD成人抑郁的有效性提供证据,可影响临床实践。

研究设计与样本

  • 多中心、随机、安慰剂对照试验,在美国3个中心随机202例CKD G3b-5合并MDD患者。
  • 先给予8周单药治疗:单盲BAT联合双盲安慰剂,或双盲安非他酮缓释片每日一次联合单盲注意控制临床管理(CM)。
  • 若抑郁缓解,继续原单药治疗8周;若未缓解,则接受安非他酮联合BAT治疗8周。
  • 对照臂为频率匹配的单盲CM联合双盲安慰剂,持续16周。

主要发现

  • 202例患者平均(SD)年龄56(12)岁,平均eGFR 24.6(10.9)ml/min/1.73 m²。
  • 42%为男性,29.7%为非裔美国人,29.4%为西班牙裔。
  • CKD G3b、G4、G5和G5D的比例分别为35.6%、43.6%、10.9%和9.9%。

关键数值与推荐

  • 主要结局为基线至16周抑郁严重度改善。
  • 次要结局包括安全性和耐受性,并探索与炎症的关联及对患者报告结局(PROs)的影响。

临床怎么用

  • 试验结果可为CKD合并MDD患者选择安非他酮、BAT或联合治疗提供循证依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Major depressive disorder (MDD) is prevalent in patients with chronic kidney disease (CKD) and is associated with adverse outcomes. Traditional pharmacologic and nonpharmacologic treatments as monotherapy have shown limited efficacy for MDD, necessitating studies of other treatment options. METHODS: The Combination of Novel Therapies for CKD Comorbid Depression Trial (CONCORD) is a multicenter, randomized, placebo-controlled trial to evaluate 2 distinct treatment strategies compared with control in participants with CKD G3b-5 and MDD, beginning with 8 weeks of monotherapy with single-blind behavioral activation teletherapy (BAT) plus double-blind placebo, or double-blind bupropion-sustained release once daily plus single-blind attention control clinical management (CM). The assigned monotherapy is continued for another 8 weeks if depression remits. If depression fails to remit, the participant will receive combination therapy with bupropion and BAT for 8 weeks. The control arm includes parallel frequency-matched single-blind CM plus double-blind placebo for 16 weeks. The primary outcome is improvement in depression severity from baseline to 16 weeks. Secondary outcomes include safety and tolerability. Association with inflammation and effects on patient-reported outcomes (PROs) will also be explored. RESULTS: A total of 202 patients were randomized across 3 US sites. Mean (SD) age was 56 (12) years and mean estimated glomerular filtration rate 24.6 (10.9) ml/min per 1.73 m2; 42% were men, 29.7% were African American, and 29.4% were Hispanic persons. The percentages with CKD G3b, G4, G5, and G5D were 35.6%, 43.6%, 10.9%, and 9.9%, respectively. CONCLUSIONS: CONCORD will provide evidence for the effectiveness of bupropion, BAT, and combination therapy for depression in adults with CKD, which can inform changes in clinical practice.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. McAdams MC, Gregg LP, Carmody T, et al. Design and Baseline Characteristics of CONCORD, a Trial of Novel Therapies for Depression in CKD. Kidney Int Rep. 2026. PMID: 42774546. doi:10.1016/j.ekir.2026.107034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。